Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations.[1]
It is the flagship company of Torrent Group which also has presence in power and city gas distribution businesses.[2]
- Market Cap ₹ 1,78,739 Cr.
- Current Price ₹ 4,691
- High / Low ₹ 5,250 / 3,672
- Stock P/E 91.7
- Book Value ₹ 480
- Dividend Yield 0.81 %
- ROCE 19.8 %
- ROE 27.6 %
- Face Value ₹ 5.00
Pros
- Company is expected to give good quarter
- Company has been maintaining a healthy dividend payout of 62.0%
Cons
- Stock is trading at 9.77 times its book value
- Promoter holding has decreased over last quarter: -7.53%
- The company has delivered a poor sales growth of 10.7% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE 500 BSE Healthcare BSE 200 BSE Dollex 200 Nifty Next 50
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3,468 | 5,439 | 4,551 | 4,244 | 5,762 | 6,168 | 6,451 | 6,742 | 7,695 | 8,533 | 9,682 | 10,712 | 14,347 | |
| Sales growth | +3% | +57% | -16% | -7% | +36% | +7% | +5% | +5% | +14% | +11% | +13% | +11% | +41% |
| 2,624 | 2,990 | 3,424 | 3,337 | 4,149 | 4,251 | 4,259 | 4,642 | 5,230 | 5,644 | 6,107 | 6,659 | 8,975 | |
| Operating Profit | 843 | 2,450 | 1,127 | 907 | 1,613 | 1,917 | 2,192 | 2,101 | 2,465 | 2,889 | 3,576 | 4,053 | 5,372 |
| OPM % | 24% | 45% | 25% | 21% | 28% | 31% | 34% | 31% | 32% | 34% | 37% | 38% | 37% |
| 306 | 292 | 300 | 332 | 382 | 237 | 118 | 204 | 82 | 91 | 7 | -52 | -177 | |
| Interest | 173 | 180 | 202 | 294 | 481 | 430 | 334 | 236 | 298 | 303 | 213 | 341 | 840 |
| Depreciation | 180 | 213 | 269 | 384 | 579 | 607 | 610 | 602 | 672 | 761 | 759 | 764 | 1,843 |
| Profit before tax | 796 | 2,348 | 955 | 562 | 935 | 1,117 | 1,366 | 1,466 | 1,577 | 1,917 | 2,610 | 2,897 | 2,512 |
| Tax % | 22% | 26% | 11% | 14% | 20% | 16% | 17% | 32% | 33% | 29% | 28% | 24% | |
| 623 | 1,743 | 854 | 482 | 745 | 939 | 1,138 | 991 | 1,051 | 1,357 | 1,888 | 2,192 | 1,876 | |
| EPS in Rs | 18.42 | 51.51 | 25.24 | 14.24 | 22.03 | 27.73 | 33.62 | 29.30 | 31.07 | 40.10 | 55.79 | 64.75 | 53.81 |
| Dividend Payout % | 31% | 34% | 28% | 49% | 39% | 58% | 52% | 82% | 71% | 70% | 57% | 59% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 11% |
| 3 Years: | 12% |
| TTM: | 41% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 14% |
| 3 Years: | 29% |
| TTM: | -9% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 27% |
| 3 Years: | 31% |
| 1 Year: | 22% |
| Return on Equity | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 22% |
| 3 Years: | 25% |
| Last Year: | 28% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 169 | 169 | 169 | 169 | 190 |
| Reserves | 2,621 | 3,623 | 4,369 | 4,472 | 4,931 | 5,036 | 5,945 | 6,261 | 6,287 | 6,660 | 7,423 | 8,283 | 18,066 |
| 2,521 | 2,249 | 2,446 | 5,845 | 5,623 | 5,294 | 4,404 | 3,348 | 4,575 | 3,344 | 2,629 | 14,277 | 13,249 | |
| 1,270 | 1,332 | 1,152 | 1,419 | 1,389 | 1,469 | 1,327 | 1,460 | 1,840 | 2,204 | 2,620 | 3,085 | 10,556 | |
| Total Liabilities | 6,497 | 7,289 | 8,051 | 11,820 | 12,027 | 11,884 | 11,761 | 11,153 | 12,872 | 12,377 | 12,842 | 25,814 | 42,061 |
| 2,764 | 2,681 | 3,523 | 7,429 | 7,425 | 7,198 | 6,741 | 6,251 | 7,972 | 7,986 | 7,554 | 7,370 | 31,862 | |
| CWIP | 628 | 984 | 473 | 447 | 498 | 536 | 588 | 568 | 698 | 226 | 402 | 420 | 400 |
| Investments | 434 | 918 | 936 | 625 | 486 | 135 | 314 | 368 | 361 | 463 | 523 | 13,172 | 2,960 |
| 2,672 | 2,705 | 3,119 | 3,319 | 3,618 | 4,016 | 4,118 | 3,966 | 3,841 | 3,701 | 4,363 | 4,851 | 6,839 | |
| Total Assets | 6,497 | 7,289 | 8,051 | 11,820 | 12,027 | 11,884 | 11,761 | 11,153 | 12,872 | 12,377 | 12,842 | 25,814 | 42,061 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1,065 | 2,403 | 676 | 929 | 1,232 | 1,580 | 1,573 | 2,140 | 2,265 | 2,893 | 2,574 | 2,731 | |
| -2,099 | -584 | -527 | -4,207 | -373 | 269 | -316 | -160 | -2,326 | -296 | -470 | -12,990 | |
| 996 | -1,326 | -130 | 2,929 | -928 | -1,555 | -1,581 | -1,977 | 81 | -2,578 | -2,104 | 10,225 | |
| Net Cash Flow | -38 | 493 | 19 | -349 | -69 | 294 | -325 | 3 | 20 | 19 | -0 | -34 |
| Free Cash Flow | 895 | 1,943 | 205 | 175 | 618 | 1,236 | 1,371 | 2,035 | 1,850 | 2,580 | 2,146 | 2,262 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 130% | 118% | 83% | 117% | 89% | 93% | 81% | 113% | 103% | 111% | 86% | 85% |
Ratios
Standalone / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 124 | 61 | 82 | 95 | 86 | 89 | 87 | 83 | 82 | 67 | 82 | 90 |
| Inventory Days | 263 | 299 | 272 | 425 | 321 | 336 | 418 | 344 | 273 | 268 | 254 | 241 |
| Days Payable | 212 | 205 | 144 | 254 | 138 | 152 | 142 | 119 | 104 | 130 | 125 | 127 |
| Cash Conversion Cycle | 175 | 155 | 209 | 267 | 269 | 273 | 364 | 308 | 251 | 205 | 211 | 204 |
| Working Capital Days | 109 | 53 | 120 | 10 | 5 | 2 | 76 | 75 | 10 | 22 | 43 | 3 |
| ROCE % | 22% | 44% | 17% | 9% | 13% | 14% | 16% | 17% | 18% | 21% | 28% | 20% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cumulative ANDA Approvals (US) approvals |
|
||||||||||
| Germany Generics Market Share % of generics market |
|||||||||||
| India IPM Rank (Position) rank (lower is better) |
|||||||||||
| R&D Expenditure as % of Revenue % of revenue |
|||||||||||
| India Base Field Force (Medical Representatives) MRs |
|||||||||||
| Brazil Field Force (Medical Representatives) MRs |
|||||||||||
| Branded Business Share of Revenue % of revenue |
|||||||||||
| Brazil IQVIA/Secondary Sales Growth % growth YoY |
|||||||||||
| R&D Expenditure (Percentage of Turnover) % |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Partial Redemption Of Ncds - INE685A07181
- Torrent Pharma redeemed and repaid ₹100 crore unlisted secured NCDs on 09-Nov-26.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- Intimation of Schedule of Investors Meet under Regulation 30 of SEBI (LODR) Regulations, 2015
-
Disclosure Under Regulation 30 Of SEBI Listing Regulations
- Commercial Tax Officer imposed ₹3.12 crore GST penalty on JB Chemicals for FY2020-21 to FY2023-24.
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Change In Corporate Address Of Kfin (RTA)
- KFin Technologies’ corporate office shifts to Hyderabad from 1 December 2026; registered office unchanged.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper advertisement in respect of special window for transfer and dematerialisation requests of physical shares
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Concalls
-
Oct 2026REC
-
Jul 2026Transcript
-
May 2026Transcript REC
-
Feb 2026Transcript REC
-
Nov 2025Transcript PPT REC
-
Jul 2025Transcript PPT
-
May 2025Transcript
-
Jan 2025Transcript
-
Oct 2024Transcript REC
-
Jul 2024Transcript
-
May 2024Transcript
-
Feb 2024Transcript
-
Aug 2023Transcript
-
May 2023Transcript
-
Sep 2022PPT
-
May 2021Transcript
-
Feb 2021Transcript
-
Oct 2020Transcript
-
Jul 2020Transcript
-
May 2020Transcript
-
Oct 2019Transcript
-
Jul 2019Transcript
-
May 2019Transcript
-
Jan 2019Transcript
-
Oct 2018Transcript
-
Jul 2018Transcript
-
May 2018PPT
-
May 2018Transcript PPT
-
Feb 2018Transcript PPT
-
Feb 2018PPT
-
Oct 2017Transcript
-
May 2017Transcript
-
Jan 2017Transcript
-
Oct 2016Transcript
-
May 2016Transcript
Product Segment FY26:
a) Branded Generics (74%):[1]
The company’s branded generics business
focuses on the manufacturing pharmaceutical products under its brand names catering
to various therapeutic segments including cardiovascular, central nervous system, gastrointestinal, vitamin mineral nutrients, dermatology, diabetes, pain management
and gynecology. Its branded generic medicines
are marketed in key regions including India
and Brazil.[2]
b) Generics (26%):
The generics segment specializes in manufacturing and supplying generic pharmaceutical products, particularly in the markets where patent exclusivity has expired or regulatory approval allows for the production of generic versions of branded drugs. This segment focuses on specific markets, including emerging and regulated ones like the US, Europe, etc. [3]